ARTICLE | Company News
BioCryst, NIH infectious news
August 18, 2014 7:00 AM UTC
BioCryst said NIH’s National Institute of Allergy and Infectious Disease (NIAID) exercised additional options to provide $4.1 million to develop the company’s BCX4430 to treat hemorrhagic fever viruses. The additional funds will be used to conduct Phase I safety trials of an intramuscular formulation of BCX4430 and efficacy studies in non-human primates to assess effective dose ranges and schedules. ...